Tourmaline Bio Elects Directors and Ratifies Auditor

Tourmaline Bio ( (TRML) ) has shared an announcement.

On June 4, 2025, Tourmaline Bio, Inc. held its annual meeting of stockholders where key decisions were made. The stockholders elected Dr. Caley Castelein and Aaron Kantoff as Class I directors to serve until 2028, and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s strategic direction and commitment to maintaining strong governance and financial oversight.

The most recent analyst rating on (TRML) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Tourmaline Bio stock, see the TRML Stock Forecast page.

Spark’s Take on TRML Stock

According to Spark, TipRanks’ AI Analyst, TRML is a Neutral.

Tourmaline Bio’s overall stock score reflects substantial financial and profitability challenges. While the technical indicators suggest some positive momentum, the negative P/E ratio and lack of dividend yield indicate valuation concerns. The strong equity position is a positive, but is overshadowed by the company’s significant cash flow issues and lack of revenue growth.

To see Spark’s full report on TRML stock, click here.

More about Tourmaline Bio

Tourmaline Bio, Inc. operates in the biotechnology industry, focusing on developing innovative therapies and solutions. The company is committed to advancing its research and development efforts to address unmet medical needs in the market.

Average Trading Volume: 364,274

Technical Sentiment Signal: Sell

Current Market Cap: $481.1M

Learn more about TRML stock on TipRanks’ Stock Analysis page.